Theglobal antibody-drug conjugates market was valued at USD 4,990.5 million in 2021. It is projected to be worth USD 33,140.3 million by 2030, registering a CAGR of 26.7% from 2022 to 2027. Antibody-drug conjugates are the anticancer drugs that offer one of the fastest-growing treatments to cancer patients, capable of exploiting the specificity of monoclonal antibodies towards targeted antigens to release potential cytotoxic drugs with increased activity and decrease in toxicity as compared to chemotherapies. The market is anticipated to show lucrative growth over the forecast period. It is mainly driven by the increasing incidence of cancer, the growing geriatric population, changing in lifestyle patterns all over the globe. The market growth is primarily supported by technological advancements and recent development in worldwide healthcare.
Additionally, the research studies in the field and timely launch of the product are also boosting the market’s growth. For instance, in 2019, the US Food and Drug Administration has approved three Antibody Drug Conjugates for various types of cancer. Thus, the growing older population and incidence of cancer coupled with advancements in the field of antibody-drug conjugates are expected to promote the revenue growth of the studied market; stringent government regulations and high costs associated with the manufacture can restrain the market growth over the forecast period.
Get Full PDF Sample Copy of Report: https://www.marketstatsville.com/request-sample/antibody-drug-conjugates-market
Thus, the growing older population and incidence of cancer coupled with advancements in the field of antibody-drug conjugates are expected to promote the revenue growth of the studied market; stringent government regulations and high costs associated with the manufacture can restrain the market growth over the forecast period.
COVID–19 Impact on the Global Antibody Drug Conjugates Market
Due to the high transmission of COVID-19, many countries have suffered many losses and continue to bear it on their economies and healthcare systems. Many countries had been in lockdown and have suspended their trades with other nations, implemented travel restrictions, etc., leading to a decline in the market capitalizations of major companies worldwide. However, the situation is found to be improving gradually with the increase in the vaccination rate.
According to the Cellular and Bioengineering Journal’s article titled ‘The Impact of COVID-19 on Cancer Risk and Treatment’, published in August 2020, reports that cancer patients are at high risk of developing severe complications following SARS-CoV-2 virus infection. It also reports that immune dysregulation and chronic inflammation may be potential drivers of severe outcomes in COVID-19-positive cancer patients. Thus, the increased complexity among the cancer-positive patients generates the need for advanced and effective therapy for the treatment and thus, drives the growth of the antibody-drug conjugates market over the forecast period.
Global Antibody Drug Conjugates Market Dynamics
Drivers: Growing Geriatric Population
With the increasing levels of life expectancy due to improvement in health facilities all over the globe, every country in the world is experiencing changes in its population structure, and both the share and growth of the older population are growing tremendously. However, as the older age population is at immense risk of getting affected by cancer, the growth of the geriatric population is projected to drive the growth of the studied market.
Additionally, the American Cancer Society’s Report titled Cancer Facts and Figures 2021 reports show that the risk of developing cancer increases with advancing age. The same source also reports that 80% of cancers in the United States are diagnosed in people 55 years of age or older. Thus, increasing geriatric population is expected to contribute to the market’s growth significantly.
Make an Enquire before Purchase @: https://www.marketstatsville.com/buy-now/antibody-drug-conjugates-market?opt=2950
Restraints: Stringent Government Regulations
The stringent regulatory framework exists for antibody-drug conjugates, which ultimately delays their quick approval and introduction in the market. Many countries and federal entities have laws that restrict industry-wide sales. Hence, it may impact the growth of the antibody-drug conjugates over the forecast period.
According to the MDPI Journal’s article titled ‘Advances and Limitations of Antibody Drug Conjugates for Cancer’ published in July 2021, reports that the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA), and the US Food and Drug Administration have strict guidelines for stability testing preceding the registration and transport of prescription medicine. Because temperature fluctuations can affect aggregation, the guidelines recommend that real-time data be provided to justify the amount of time a drug product can be left out of the refrigerator before being returned to its recommended temperature.
Scope of the Antibody Drug Conjugates
The study categorizes the antibody-drug conjugates market based on product, technology, target, application, and end-users at the regional and global levels.
By Product Type Outlook (Sales, USD Million, 2017–2030)
- Other Product Type
By Technology Outlook (Sales, USD Million, 2017–2030)
- Cleavable Linker
- Non-Cleavable Linker
By Target Type Outlook (Sales, USD Million, 2017–2030)
- CD30 Antibodies
- HER2 Antibodies
- Other Target Types
By Application Outlook (Sales, USD Million, 2017–2030)
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Other Applications
By End-Users Outlook (Sales, USD Million, 2017–2030)
- Hospitals and Speciality Cancer Centers
- Other End Users
By Region Outlook (Sales, USD Million, 2017–2030)
- North America (US, Canada, Mexico)
- South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
- Europe (Germany, Italy, France, UK, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, the Netherlands, Norway, Sweden, Denmark, Rest of Europe)
- Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, the Philippines, Singapore, Australia & New Zealand, Rest of Asia Pacific)
- The Middle East & Africa (Saudi Arabia, UAE, South Africa, Northern Africa, Rest of MEA)
Request for Complete TOC and Figures & Graphs @ https://www.marketstatsville.com/table-of-content/antibody-drug-conjugates-market
The Kadcyla segment is projected to account for the largest market share, by product type
Based on product type, the global antibody-drug conjugates market is divided into Adcetris, Kadcyla, and other product types. In 2021, the Kadcyla segment accounted for the largest market share of 49.1% in the global antibody-drug conjugates market. Kadcyla ( API: ado-trastuzumab emtansine) is currently available as an injectable for intravenous use only. The drug got its first approval in the United States in 2013, and it is currently one of the leading drugs in the market, owing to its high potency and efficacy in wide indications.
The increased demand for Kadcyla was driven by its usage in the early breast cancer setting and the ongoing clinical trials. In June 2020, NICE published the final guidance backing NHS use of Roche’s Kadcyla for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer in people who have already had therapy to shrink their tumor but have residual disease in the breast or surrounding lymph nodes before surgery to remove the tumor.
North America accounts for the highest CAGR during the forecast period
North America, Asia-Pacific, Europe, South America, and the Middle East & Africa are the regions in which the global antibody-drug conjugates market has been segmented. Globally, North America is estimated to hold the highest CAGR of 27.4% in the global antibody-drug conjugates market during the forecast period. The region includes the countries such as the US, Canada, Mexico.
After North America, Europe is the fastest growing region with a CAGR of 26.7% during the forecast period. The factors such as a rise in incidences of cancer, an increase in the geriatric population, and an increase in investments in research and development are some of the factors driving the market of antibody-drug conjugates in Europe. According to the estimations of the International Agency for Research on Cancer Globocan 2020 report, there were approximately 628,519 new cases of cancer in Germany in 2020. According to the report, the most common cancers in Germany are breast cancer, lung cancer, prostate, and colon cancer. The high incidence of cancer is indicative of the need to develop novel therapies like antibody-drug conjugates that can effectively reduce the burden, due to which there is expected to be scope for market growth.
Request For Report Description @ https://www.marketstatsville.com/antibody-drug-conjugates-market
Key Market Players
The antibody-drug conjugates market is mildly concentrated in nature with few numbers global players operating in the market such as Novartis AG, Takeda Pharmaceutical Company Limited, F. Hoffman-La Roche Ltd., Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Progenics Pharmaceuticals Inc., Immunomedics, Inc., Bayer Healthcare Pharmaceuticals., Agensys, Inc., Concortis Biotherapeutics, Celldex Therapeutics Inc., Sanofi S.A., and Synthon Holding B.V.